help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Published ahead of print on July 20, 2006, doi:10.1164/rccm.200508-1237OC
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Online Supplement
Right arrow All Versions of this Article:
200508-1237OCv1
174/8/906    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sato, T.
Right arrow Articles by Ishigatsubo, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sato, T.
Right arrow Articles by Ishigatsubo, Y.
American Journal of Respiratory and Critical Care Medicine Vol 174. pp. 906-914, (2006)
© 2006 American Thoracic Society
doi: 10.1164/rccm.200508-1237OC

Original Article

Heme Oxygenase-1, a Potential Biomarker of Chronic Silicosis, Attenuates Silica-induced Lung Injury

Takashi Sato, Mitsuhiro Takeno, Koichi Honma, Hideyuki Yamauchi, Yoshiaki Saito, Takao Sasaki, Hiroshi Morikubo, Yoji Nagashima, Shigeto Takagi, Kouichi Yamanaka, Takeshi Kaneko and Yoshiaki Ishigatsubo

Department of Internal Medicine and Clinical Immunology, and Department of Pathology, Yokohama City University, Yokohama; Department of Pathology, Dokkyo University School of Medicine; Department of Internal Medicine, and Department of Radiology, Rosai Hospital for Silicosis, Tochigi; and Seamen's Insurance AMHTS Clinic, Yokohama, Japan

Correspondence and requests for reprints should be addressed to Professor Yoshiaki Ishigatsubo, Department of Internal Medicine and Clinical Immunology, Yokohama City University, 3-9 Fukuura, Kanazawa-ku, Yokohama, 236-0004, Japan. E-mail: ishigats{at}med.yokohama-cu.ac.jp


   ABSTRACT
TOP
 ABSTRACT
METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Rationale: Heme oxygenase-1 (HO-1), a rate-limiting enzyme in heme catabolism, has antioxidative, antiapoptotic, and antiinflammatory activities. We examined whether HO-1 might be involved in silicosis.

Objectives: To investigate whether HO-1 can reduce silicosis in mice and humans.

Methods and measurements: Silicosis was studied using a murine model, and in 46 male patients. Serum HO-1 and 8-hydroxydeoxyguanosine (a marker of oxidative stress) were measured by enzyme-linked immunosorbent assay. Levels of HO-1 were measured by immunohistochemistry and immunoblotting.

Main results: Serum HO-1 levels were significantly elevated in patients with silicosis compared with age-matched control subjects or patients with chronic obstructive pulmonary disease. Serum HO-1 levels also correlated inversely with serum 8-hydroxydeoxyguanosine levels and positively with vital capacity and forced expiratory volume in one second in patients with silicosis. HO-1 was present in the lungs of humans and mice with silicosis, especially at sites of silica particle deposition. In mice, silica exposure was associated with acute leukocyte infiltration, leading to development of silicotic lung lesions. The inflammation was suppressed by treatment with hemin, an inducer of HO-1, and enhanced by zinc protoporphyrin, an inhibitor of HO-1.

Conclusions: Pulmonary HO-1 expression is increased in silicosis. HO-1 suppresses reactive oxygen species activity, and subsequent pathologic changes, thereby attenuating disease progression.

Key Words: antioxidants • occupational diseases • oxidative stress

Inhalation of crystalline silica for prolonged periods can lead to silicosis, an inflammatory disorder (1, 2). The acute manifestations of this disease include inflammation and apoptosis, with attendant destruction of the lung tissue (3), whereas chronic silicosis is characterized by progressive fibrosis and emphysematous changes (4). Although lung function is severely impaired in patients with advanced disease, airway obstruction is common even in silica-exposed workers with no radiological abnormalities (4, 5). Defining the molecular mechanisms triggered by exposure to silica could facilitate early diagnosis by identifying markers of early disease, and could elucidate novel therapeutic strategies.

Crystalline silica induces the production of reactive oxygen species (ROS) (2), which play a key role in the development of silicosis (6) via the mitogen-activated protein kinase (MAPK) pathway (7). ROS cause direct tissue injury and activation of alveolar macrophages to undergo apoptosis (8), enhance the synthesis of proinflammatory cytokines (9), and augment the induction of inflammatory responses via the MAPK-dependent pathways (10). Silica-induced oxidative DNA damage, reflected by an increase in 8-hydroxydeoxyguanosine (8-OHdG), is associated with an increased risk of carcinogenesis (11). ROS production is down-regulated by elements of the extracellular signal-regulated kinase (ERK) pathway, which trigger increased transcription of antioxidants (12).

One of the antioxidants that protect against ROS-induced airway inflammation is heme oxygenase (HO)-1, an enzyme that degrades heme into bilirubin, Fe2+, and carbon monoxide (CO) (13, 14). Lung epithelial cells, smooth muscle cells, macrophages, and endothelial cells can all produce HO-1 (15–17). The protective activity of HO-1 was established in several model systems. For example, adenovirus-mediated gene transfer of HO-1 cDNA suppresses lipopolysaccharide-induced lung injury (18), influenza-induced pneumonia (19), and bleomycin-induced pulmonary fibrosis (20) in murine models. The current work explores whether HO-1 can play a role in attenuating silica-mediated lung injury.

We evaluated HO-1 protein levels in sera from patients with silicosis and in a murine model of that disease. To clarify the role of HO-1, we assessed the effects of hemin and zinc protoporphyrin (ZnPP) (an inducer and an inhibitor of HO-1, respectively) in murine silicosis. Abbreviated results from this study were previously reported in abstract form (21, 22).


   METHODS
TOP
 ABSTRACT
 METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
For a detailed description of the methods, see the online supplement.

Patients
Forty-six male patients (age range, 56–83 yr) were diagnosed as having silicosis on the basis of their occupational history and the International Labor Organization (ILO) International Classification of Radiographs of Pneumoconioses (23). Radiographic opacities were graded on a 12-point scale using the ILO system (score of 1 for 0/– and 12 for 3/+) (24). More details are shown in the online supplement. Twenty-seven male patients with chronic obstructive pulmonary disease (COPD) (age range, 60–87 yr) and 42 healthy male volunteers (age range, 55–80 yr) served as age-matched disease and normal control subjects, respectively. Subjects were defined as smokers if they had smoked at least 1 pack-year, and as ex-smokers if they had stopped smoking for at least 1 yr (25). Serum HO-1 and 8-OHdG were measured by enzyme-linked immunosorbent assay (ELISA). C-reactive protein (CRP) in serum was analyzed by immunonephelometry (26). Spirometry was performed using standard protocols according to the American Thoracic Society recommendations (27). Local HO-1 expression was examined by immunohistochemistry in the lungs from 10 patients with silicosis (8 autopsies and 2 surgical specimens) and from 17 control autopsy cases with no occupational lung diseases. In silicosis samples, HO-1–positive cells were counted microscopically in 50 high-power fields (HPF) (approximately equivalent to 10 mm2) containing areas of silicotic fibrosis; in control samples, this was done in 50 randomly selected HPF. The study was approved by the local Institutional Review Board. All patient studies were performed after obtaining written informed consent, except for the studies on autopsy samples, for which the need for informed consent was waived.

Murine Silicosis Model
Six-week-old male BALB/c mice were used for all animal experiments. All studies were approved by the Institutional Animal Care and Use Committee at Yokohama City University. Under anesthesia with ketamine (80 mg/kg; Sigma-Aldrich, St. Louis, MO) and xylazine (10 mg/kg; Sigma), 100 mg/kg of sterilized crystalline silica (Min-U-Sil-5, U.S. Silica, Berkeley Springs, WV) in 100 µl of sterile saline were instilled into the trachea (28). In some experiments, 100 µmol/kg hemin (Sigma) or ZnPP (Porphyrin Products, Logan, UT) were administered intraperitoneally at 0.5–48 h before silica administration (18). Cell differentials were determined in bronchoalveolar lavage fluid (BALF), obtained by tracheal cannulation using five washes with 0.8-ml aliquots of PBS/wash (29). Plasma 8-OHdG was measured by ELISA. HO-1 in the lung was monitored using immunohistopathologic and immunoblotting techniques.

Statistics
Values were expressed as mean ± SEM. In the mouse studies, only nonparametric methods were used for statistical analysis. Comparisons between multiple independent groups were made by Kruskal Wallis test followed by Mann-Whitney U test. In the human studies, comparisons between study groups were made by using one-way ANOVA followed by post hoc analysis with the Bonferroni test. The relationships between serum HO-1 and other laboratory data were examined by using linear regression analysis with the method of least squares. Probability values of less than 0.05 were considered statistically significant.


   RESULTS
TOP
 ABSTRACT
 METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
Serum HO-1 Levels Are Increased in Patients with Mild Silicosis
The characteristics of the 46 patients with silicosis, 27 patients with COPD, and 42 normal control subjects are shown in Tables 1 and 2. The patients with silicosis and COPD had longer smoking histories than did control subjects, and the majority of patients were ex-smokers. Vital capacity (VC) and/or forced expiratory volume in one second (FEV1) were < 80% of predicted values (30) in 21/46 patients with silicosis, a significant reduction when compared with control subjects. Patients with COPD had reduced FEV1 but not VC when compared with control subjects but not patients with silicosis. The silicosis group included patients with disease of varying radiologic severity (28 simple silicosis and 18 complicated silicosis) (Table 2). Of the 46 patients, 43 had an ILO profusion of >= 1/0 (with or without large opacities) and four had large opacities only. Some of the patients with silicosis or COPD were being treated with theophylline (32.6% and 40.7%, respectively), short-acting beta-agonists (28.3% and 25.9%, respectively), anticholinergics (26.1% and 37.0%, respectively), and/or inhaled corticosteroids (8.7% and 22.2%, respectively).


View this table:
[in this window]
[in a new window]
  		TABLE 1. DEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF THE STUDY GROUPS

 

View this table:
[in this window]
[in a new window]
  		TABLE 2. CHARACTERISTICS OF PATIENTS WITH SILICOSIS

 
Serum CRP levels were significantly higher in patients with silicosis than those with COPD or control subjects (Table 1). Serum HO-1 levels were also significantly higher in patients with silicosis than the other groups (Table 1). Patients with silicosis with only mildly impaired respiratory function showed the highest serum HO-1 levels. Thus, increased HO-1 levels correlated positively with FEV1 (r = +0.390, p = 0.008) and VC (r = +0.296, p = 0.046) (Table 3). Other factors examined, including age, duration of silica exposure, smoking history, or serum CRP, did not correlate with serum HO-1 levels. Among patients with silicosis, occupational history did not correlate with serum HO-1 levels. In contrast to patients with silicosis, lung function parameters and HO-1 levels did not correlate in patients with COPD (data not shown).


View this table:
[in this window]
[in a new window]
  		TABLE 3. CORRELATION BETWEEN SERUM HEME OXYGENASE-1 AND VARIABLES FROM THE PATIENTS WITH SILICOSIS

 
Serum 8-OHdG levels were significantly higher in silicosis patients than those with COPD or healthy control subjects (Table 1). Furthermore, a significant negative correlation was found between serum HO-1 and 8-OHdG levels (r = –0.311, p = 0.035) (Table 3).

Localization of HO-1 Protein in Silicosis Lungs
Since elevated serum HO-1 was preferentially found in patients with silicosis, we examined HO-1 expression in the lung lesions. Surgical specimens from 2 patients with silicosis and with lung cancer, 8 autopsied subjects with silicosis, and 17 control subjects were studied (Table 4). HO-1 protein was detected by immunohistochemical staining in bronchial epithelial cells (Figure 1) and macrophages (Figure 2) of granulomatous tissue from areas free of tumor. Silica particles were consistently associated with lesions containing HO-1–expressing cells (Figure 1). The number of HO-1–expressing cells was significantly higher in patients with silicosis than in control subjects (HO-1–positive cell number/cm2; 409 ± 72 versus 39 ± 12, p < 0.05) (Table 4).


Figure 1
View larger version (52K):
[in this window]
[in a new window]
  		Figure 1. Histologic and immunohistochemical features of lung samples from patients with silicosis. HO-1 expression (red) was present in bronchial epithelial cells containing polarizing particles. (A) Hematoxylin and eosin, (B) HO-1 immunostaining, (C) polarizing microscopy. Magnification: x400. The figures are representative of samples from 10 patients with silicosis.

 

Figure 2
View larger version (188K):
[in this window]
[in a new window]
  		Figure 2. HO-1 expression in silicotic nodules. Macrophages (red) stained with anti–HO-1 mAb were present in the central and peripheral areas of silicotic nodules. A high-power photomicrograph is shown in the inset. (A) Hematoxylin and eosin, (B) HO-1 immunostaining, (C) CD68 immunostaining in serial sections, (D) negative control (nonspecific mouse IgG). Magnification: x100 (inset x400). The figures are representative of samples from 10 patients with silicosis.

 

View this table:
[in this window]
[in a new window]
  		TABLE 4. DEMOGRAPHIC DATA OF SURGERY AND AUTOPSY SUBJECTS

 
HO-1 Expression in Murine Silicosis
A murine model of silicosis was studied to clarify the role of HO-1. Disease was induced by administering crystalline silica intratracheally to BALB/c mice. This resulted in acute leukocyte infiltration followed by granuloma formation similar to that observed in human silicosis (Figure E1 in the online supplement). Immunohistochemical analysis showed that HO-1 expression had increased in bronchial epithelial cells within 1 d of silica exposure (Figure 3). HO-1–expressing cells were also found in granulomatous tissues during the chronic phase of disease (Figure 4). Consistent with results from the human lung biopsies, HO-1–expressing cells were found close to silica particles deposited in the lungs throughout the clinical course of disease in mice (Figure 4). Semiquantitative analysis of HO-1 protein by immunoblotting indicated that HO-1 expression in the lungs gradually increased as disease progressed (Figures 5A and 5B).


Figure 3
View larger version (203K):
[in this window]
[in a new window]
  		Figure 3. Immunohistochemical staining for HO-1 in mice with silicosis. HO-1 immunostaining in the lung sections from control mice (A), or mice with silica-induced lung injury on Day 1 (B), Day 14 (C), or Week 12 (D). Immunohistochemistry detected HO-1 expression in bronchial epithelial cells (B, Day 1), and granulomatous lesions (C, Day 14; D, Week 12) (magnification: x100).

 

Figure 4
View larger version (199K):
[in this window]
[in a new window]
  		Figure 4. High-power photomicrographs of HO-1–positive granulomatous lesions 12 wk after silica instillation in mice (magnification: x400). (A) HO-1 immunostaining. (B) Polarizing microscopy of the same field as in A indicates that HO-1–positive macrophages phagocytized silica particles. (C) F4/80 immunostaining. (D) Negative control (rat IgG).

 

Figure 5
View larger version (28K):
[in this window]
[in a new window]
  		Figure 5. Time course of HO-1 expression in the lung and plasma 8-OHdG level in silicosis model mouse. (A) Immunoblotting analysis of HO-1 in the microsomal fraction of mouse silicosis lungs. (B) Semiquantitative analysis of immunoblots with anti–HO-1 mAb showed a gradual increase in HO-1 protein in the lung after silica exposure. Four mice were examined at each time point (*p < 0.05 versus control). (C) Plasma 8-OHdG levels were determined by ELISA. The level was increased until 12 wk after silica instillation and then returned to baseline (*p < 0.05, **p < 0.01 versus control). Data are shown as mean ± SEM. Numbers inside the bars indicate the number of mice investigated in each group.

 
Plasma 8-OHdG concentrations gradually increased through 12 wk, and then decreased to the baseline by 24 wk (Figure 5C). This contrasts with the persistent elevation in HO-1 expression late in the disease process (Figures 5A and 5B).

Super-induction of HO-1 Attenuates Acute Silicosis in Mice
Consistent with the acute inflammatory responses caused by silica in the lower respiratory tract (31), neutrophils were the dominant cells in BALF during the first 3 d after silica exposure; later macrophages and lymphocytes became dominant (Figure 6).


Figure 6
View larger version (28K):
[in this window]
[in a new window]
  		Figure 6. Effects of pretreatment with hemin or ZnPP in the murine silicosis model. (A) Total cell number in the BALF 1–14 d after silica exposure. The cell number was significantly reduced by pre-treatment with hemin (*p < 0.05 versus silica alone, n = 4–5 mice each), and significantly increased by ZnPP (*p < 0.05 versus silica alone, n = 4–5 mice each). (B) Neutrophils (PMN) were significantly reduced or elevated after Day 1 in mice pretreated with hemin or ZnPP, respectively (*p < 0.05 versus silica alone, n = 4–5 mice each). (C) Macrophages were significantly reduced after Day 7 in hemin-pretreated mice (*p < 0.05 versus silica alone, n = 4–5 mice each). (D) Lymphocytes were significantly enhanced after Day 7 in ZnPP-pretreated mice (*p < 0.05 versus silica alone, n = 4–5 mice each). Data are shown as mean ± SEM of four or five experiments.

 
To evaluate the impact of HO-1 on the development of silicosis, mice were treated with hemin, a potent HO-1 inducer, or ZnPP, an inhibitor of HO. In normal mice, a single administration with hemin induced sustained HO-1 expression for at least 7 d, whereas ZnPP had no effect (Figure E2). In mice with silicosis, HO-1 expression in the lung was enhanced by hemin and suppressed by ZnPP (Figures 7A and 7B). Infiltrating cell numbers were decreased by hemin but increased by ZnPP (Figure 6A). Hemin pretreatment reduced neutrophil infiltration and the subsequent accumulation of macrophages, whereas ZnPP pretreatment enhanced the influx of neutrophils and the subsequent accumulation of lymphocytes (Figures 6B–6D). Histopathologic analysis showed that cellular infiltration into alveolar spaces was suppressed by hemin but augmented by ZnPP (Figure E1A). Thus, hemin suppressed acute inflammation after silica exposure, whereas lesion development was accelerated by ZnPP.


Figure 7
View larger version (29K):
[in this window]
[in a new window]
  		Figure 7. Effects of hemin and ZnPP on HO-1 expression and plasma 8-OHdG levels in murine silicosis. (A) Lung immunoblots demonstrated that HO-1 expression was up- or down-regulated by pretreatment with hemin or ZnPP, respectively (n = 4 at each time point of each group). (B) Semiquantitative analysis of HO-1/actin expression by densitometry (n = 4 at each time point of each group; *p < 0.05 versus silica alone). (C) Plasma 8-OHdG determined by ELISA was significantly reduced 1 d after hemin pretreatment of mice and was elevated 2 d after ZnPP pretreatment of mice (n = 4–7 at each time point of each group). Data are shown as mean ± SEM (*p < 0.05 versus silica alone).

 
The silica-induced increases in plasma 8-OHdG levels were markedly increased by pretreatment with ZnPP and suppressed by hemin (Figure 7C). There was an inverse correlation between lung HO-1 and plasma 8-OHdG levels (Figures 7A–7C). This observation is consistent with the finding that serum HO-1 levels were not elevated in patients with silicosis with high serum levels of 8-OHdG.


   DISCUSSION
TOP
 ABSTRACT
 METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
More than 10,000 patients with silicosis are currently followed up in Japan, although the incidence has been gradually decreasing due to efforts to prevent further silica exposure (32). Unfortunately, silicosis continues to occur in many developing countries (due to a paucity of preventive medicine) and in some advanced countries (especially in the fields of chemical and civil engineering, where workers are exposed to silica-containing dusts) (33). Although this disease can be prevented by avoiding silica exposure, equally important is the development of therapy for those with pre-existing disease.

This work is the first to demonstrate that HO-1 is synthesized in the lungs of patients with silicosis, thus contributing to a significant elevation of serum HO-1 levels in patients. Our studies suggest that the lung is a major source of circulating HO-1, since silicotic nodules contain abundant HO-1–expressing cells. In contrast, peripheral blood mononuclear cells (PBMC) are unlikely to be the source of serum HO-1, both because HO-1 expression was not elevated in PBMC from patients with silicosis and HO-1 protein levels in serum did not correlate with protein production by PBMC (r = +0.185, p = 0.301) (unpublished observations). If serum HO-1 derives primarily from lung lesions, it could provide a novel biomarker for evaluating the severity of silicosis.

Although HO-1 expression in the lung is increased in diseases characterized by increased oxidative stress (34, 35), changes in serum HO-1 levels have not been reported in pulmonary disorders. We previously demonstrated that serum HO-1 levels were elevated in patients with adult-onset Still's disease and hemophagocytic syndrome, two systemic inflammatory disorders characterized by hyper-ferritinemia and macrophage activation, and that serum HO-1 levels correlate closely with disease activity (36).

Our present results indicate that serum HO-1 levels correlate significantly with FEV1 and VC in patients with silicosis. A previous necropsy study revealed that pathologic changes in the lung parenchyma and large airways were associated with impairment of lung function in patients with silicosis (37). Although involvement of ROS and increased circulating carbon monoxide levels are present in patients with COPD (38, 39), serum HO-1 levels are not elevated in those patients (whose lung function is comparable to those with silicosis). Rather, data from human lung samples and from experimental silicosis in mice indicates that silica exposure directly and persistently induces HO-1 expression in granulomatous lung tissue.

The present study examined HO-1 expression in human lung samples. Considerable care was taken to ensure that studies involving these samples were free from artifacts (potentially introduced due to the terminal stage of illness, postmortem phenomena, and/or extrapulmonary disease). Several groups have shown that HO-1 can be accurately detected in autopsy material (40–42). Moreover, there were no differences between surgically resected versus autopsied lung tissue with respect to levels of HO-1 expression (HO-1–positive cell number/cm2; 414 ± 204 versus 407 ± 88), suggesting that the terminal stage of disease did not affect expression of this protein. Finally, lungs from patients with various extrapulmonary diseases expressed HO-1 at levels far below those found in silicotic lungs.

There is accumulating evidence that HO-1 helps protect the host from progression of certain inflammatory diseases (43). In the current study, super-induction of HO-1 by administration of hemin suppressed silica-induced leukocyte infiltration in the lung, whereas treatment with ZnPP augmented it. When hemin was administered to normal mice (without silica exposure), HO-1 expression was induced in the lung, and persisted for at least 7 d (Figure E2). ZnPP did not alter HO-1 expression level in the absence of silica exposure, but did suppress HO-1 expression, leukocyte infiltration, and subsequent pathologic changes in mice with silicosis (Figure 7). This discrepancy suggests that ZnPP does not directly act on HO-1 expression but instead suppresses a mediator induced by silica that stimulates HO-1 expression.

ROS play a critical role in the development of silicosis (2). In addition to causing direct tissue toxicity, ROS damage nuclear and mitochondrial DNA, leading to increased generation of 8-OHdG (44). In the murine silicosis model, plasma 8-OHdG levels were elevated from 1–12 wk after particle exposure and then returned to baseline by 24 wk. In contrast, HO-1 expression was persistently increased in lungs of mice with silicosis. The dissociation between lung HO-1 expression and plasma levels of 8-OHdG may have several explanations. First, because ROS activity reflects the balance between oxidative stress and antioxidant systems (45), it is likely that antioxidant activity exceeds silica-induced ROS after 12 wk in this model. Second, by 12 wk, some of the silica particles may have left the lung via the lymphatics (accumulation of silica in the draining lymph nodes was confirmed histologically). The negative relationship between 8-OHdG and HO-1 was particularly evident in mice treated with hemin or ZnPP. Hemin enhanced the expression of HO-1 while reducing 8-OHdG levels compared with controls, whereas ZnPP treatment had the opposite effects. Indeed, serum 8-OHdG levels were increased in patients with silicosis having normal serum HO-1 levels. Previous studies suggest that ROS are generated via the Fenton mechanism after silica exposure (2), and that HO-1 acts as an important scavenger of ROS (46, 47), probably via the heme degradation products bilirubin and CO (43).

In summary, the present study shows that HO-1 is persistently expressed in the lung lesions of patients with silicosis. This appears to reflect the induction of ROS by silica, leading to an elevation in serum HO-1 levels. The increased HO-1 can protect the host by suppressing silica-induced ROS activity. Thus, upregulation of HO-1 may represent a novel strategy for the treatment of silicosis.


   Acknowledgments
 
The authors thank Dennis M. Klinman (Center for Biologics Evaluation and Research, FDA) for helpful discussions and Toshihiro Shibata, CT (Division of Pathology, Rosai Hospital for Silicosis) for technical help. The authors also thank the nursing and laboratory staff of Rosai Hospital for Silicosis.


   FOOTNOTES
 
This work was supported in part by grants from The Yokohama City University Center of Excellence Program, and grant (No.16590991) from the Ministry of Education, Culture, Sports, Science and Technology of Japan.

This article has an online supplement, which is accessible from this issue's table of contents at www.atsjournals.org.

Originally Published in Press as DOI: 10.1164/rccm.200508-1237OC on July 20, 2006

Conflict of Interest Statement: None of the authors has a financial relationship with a commercial entity that has an interest in the subject of this manuscript.

Received in original form August 10, 2005; accepted in final form July 18, 2006


   REFERENCES
TOP
 ABSTRACT
 METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Castranova V, Vallyathan V. Silicosis and coal workers' pneumoconiosis. Environ Health Perspect 2000;108:675–684.[Medline]
  2. Fubini B, Hubbard A. Reactive oxygen species (ROS) and reactive nitrogen species (RNS) generation by silica in inflammation and fibrosis. Free Radic Biol Med 2003;34:1507–1516.[CrossRef][Medline]
  3. Borges VM, Lopes MF, Falcao H, Leite-Junior JH, Rocco PR, Davidson WF, Linden R, Zin WA, DosReis GA. Apoptosis underlies immunopathogenic mechanisms in acute silicosis. Am J Respir Cell Mol Biol 2002;27:78–84.[Abstract/Free Full Text]
  4. Hnizdo E, Vallyathan V. Chronic obstructive pulmonary disease due to occupational exposure to silica dust: a review of epidemiological and pathological evidence. Occup Environ Med 2003;60:237–243.[Abstract/Free Full Text]
  5. Humerfelt S, Eide GE, Gulsvik A. Association of years of occupational quartz exposure with spirometric airflow limitation in Norwegian men aged 30–46 years. Thorax 1998;53:649–655.[Abstract/Free Full Text]
  6. Vallyathan V, Castranova V, Pack D, Leonard S, Shumaker J, Hubbs AF, Shoemaker DA, Ramsey DM, Pretty JR, McLaurin JL, et al. Freshly fractured quartz inhalation leads to enhanced lung injury and inflammation. Potential role of free radicals. Am J Respir Crit Care Med 1995;152:1003–1009.[Abstract]
  7. Ding M, Shi X, Dong Z, Chen F, Lu Y, Castranova V, Vallyathan V. Freshly fractured crystalline silica induces activator protein-1 activation through ERKs and p38 MAPK. J Biol Chem 1999;274:30611–30616.[Abstract/Free Full Text]
  8. Shen HM, Zhang Z, Zhang QF, Ong CN. Reactive oxygen species and caspase activation mediate silica-induced apoptosis in alveolar macrophages. Am J Physiol Lung Cell Mol Physiol 2001;280:L10–L17.[Abstract/Free Full Text]
  9. Gossart S, Cambon C, Orfila C, Seguelas MH, Lepert JC, Rami J, Carre P, Pipy B. Reactive oxygen intermediates as regulators of TNF-alpha production in rat lung inflammation induced by silica. J Immunol 1996;156:1540–1548.[Abstract]
  10. Janssen-Heininger YM, Macara I, Mossman BT. Cooperativity between oxidants and tumor necrosis factor in the activation of nuclear factor (NF)-kappaB: requirement of Ras/mitogen-activated protein kinases in the activation of NF-kappaB by oxidants. Am J Respir Cell Mol Biol 1999;20:942–952.[Abstract/Free Full Text]
  11. Shi X, Castranova V, Halliwell B, Vallyathan V. Reactive oxygen species and silica-induced carcinogenesis. J Toxicol Environ Health B Crit Rev 1998;1:181–197.[Medline]
  12. Papaiahgari S, Kleeberger SR, Cho HY, Kalvakolanu DV, Reddy SP. NADPH oxidase and ERK signaling regulates hyperoxia-induced Nrf2-ARE transcriptional response in pulmonary epithelial cells. J Biol Chem 2004;279:42302–42312.[Abstract/Free Full Text]
  13. Choi AM, Alam J. Heme oxygenase-1: function, regulation, and implication of a novel stress-inducible protein in oxidant-induced lung injury. Am J Respir Cell Mol Biol 1996;15:9–19.[Abstract]
  14. Otterbein LE, Mantell LL, Choi AM. Carbon monoxide provides protection against hyperoxic lung injury. Am J Physiol 1999;276:L688–L694.
  15. Donnelly LE, Barnes PJ. Expression of heme oxygenase in human airway epithelial cells. Am J Respir Cell Mol Biol 2001;24:295–303.[Abstract/Free Full Text]
  16. Lim S, Groneberg D, Fischer A, Oates T, Caramori G, Mattos W, Adcock I, Barnes PJ, Chung KF. Expression of heme oxygenase isoenzymes 1 and 2 in normal and asthmatic airways: effect of inhaled corticosteroids. Am J Respir Crit Care Med 2000;162:1912–1918.[Abstract/Free Full Text]
  17. Samb A, Taille C, Almolki A, Megret J, Staddon JM, Aubier M, Boczkowski J. Heme oxygenase modulates oxidant-signaled airway smooth muscle contractility: role of bilirubin. Am J Physiol Lung Cell Mol Physiol 2002;283:L596–L603.[Abstract/Free Full Text]
  18. Inoue S, Suzuki M, Nagashima Y, Suzuki S, Hashiba T, Tsuburai T, Ikehara K, Matsuse T, Ishigatsubo Y. Transfer of heme oxygenase 1 cDNA by a replication-deficient adenovirus enhances interleukin 10 production from alveolar macrophages that attenuates lipopolysaccharide-induced acute lung injury in mice. Hum Gene Ther 2001;12:967–979.[CrossRef][Medline]
  19. Hashiba T, Suzuki M, Nagashima Y, Suzuki S, Inoue S, Tsuburai T, Matsuse T, Ishigatubo Y. Adenovirus-mediated transfer of heme oxygenase-1 cDNA attenuates severe lung injury induced by the influenza virus in mice. Gene Ther 2001;8:1499–1507.[CrossRef][Medline]
  20. Tsuburai T, Suzuki M, Nagashima Y, Suzuki S, Inoue S, Hasiba T, Ueda A, Ikehara K, Matsuse T, Ishigatsubo Y. Adenovirus-mediated transfer and overexpression of heme oxygenase 1 cDNA in lung prevents bleomycin-induced pulmonary fibrosis via a Fas-Fas ligand-independent pathway. Hum Gene Ther 2002;13:1945–1960.[CrossRef][Medline]
  21. Sato T, Takeno M, Kaneko T, Kirino Y, Nagashima Y, Yamauchi H, Saito Y, Sasaki T, Honma K, Ishigatsubo Y. Heme oxygenase-1 correlates with oxidative DNA damage in silicotic patients. Proc Am Thorac Soc 2005;2:A443.
  22. Sato T, Kaneko T, Takeno M, Nagashima Y, Okamura M, Kobayashi N, Miura K, Shinohara T, Mishima W, Ishigatsubo Y. Protective effects of heme oxygenase-1 on silica-induced lung injury. Proc Am Thorac Soc 2005;2:A817.
  23. International Labour Organization. Guidelines for the use of the ILO international classification of radiographs of pneumoconioses. Occupational Safety and Health Series No.22 Geneva, Switzerland. 2000.
  24. Arakawa H, Honma K, Saito Y, Shida H, Morikubo H, Suganuma N, Fujioka M. Pleural disease in silicosis: pleural thickening, effusion, and invagination. Radiology 2005;236:685–693.[Abstract/Free Full Text]
  25. Jegal Y, Kim DS, Shim TS, Lim CM, Do Lee S, Koh Y, Kim WS, Kim WD, Lee JS, Travis WD, et al. Physiology is a stronger predictor of survival than pathology in fibrotic interstitial pneumonia. Am J Respir Crit Care Med 2005;171:639–644.[Abstract/Free Full Text]
  26. Kaditis AG, Alexopoulos EI, Kalampouka E, Kostadima E, Germenis A, Zintzaras E, Gourgoulianis K. Morning levels of C-reactive protein in children with obstructive sleep-disordered breathing. Am J Respir Crit Care Med 2005;171:282–286.[Abstract/Free Full Text]
  27. American Thoracic Society. Standardization of spirometry: 1994 Update. ATS Statement. Am J Respir Crit Care Med 1995;152:1107–1136.[Medline]
  28. Barbarin V, Arras M, Misson P, Delos M, McGarry B, Phan SH, Lison D, Huaux F. Characterization of the effect of interleukin-10 on silica-induced lung fibrosis in mice. Am J Respir Cell Mol Biol 2004;31:78–85.[Abstract/Free Full Text]
  29. Nemmar A, Nemery B, Hoet PHM, Van Rooijen N, Hoylaerts MF. Silica particles enhance peripheral thrombosis: key role of lung macrophage-neutrophil cross-talk. Am J Respir Crit Care Med 2005;171:872–879.[Abstract/Free Full Text]
  30. Itoh T, Nagaya N, Yoshikawa M, Fukuoka A, Takenaka H, Shimizu Y, Haruta Y, Oya H, Yamagishi M, Hosoda H, et al. Elevated plasma ghrelin level in underweight patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004;170:879–882.[Abstract/Free Full Text]
  31. Driscoll KE, Lindenschmidt RC, Maurer JK, Higgins JM, Ridder G. Pulmonary response to silica or titanium dioxide: inflammatory cells, alveolar macrophage-derived cytokines, and histopathology. Am J Respir Cell Mol Biol 1990;2:381–390.[Medline]
  32. Takahashi K. The silica carcinogenicity issue in Japan. Occup Environ Med 2003;60:897–898.[Free Full Text]
  33. Verma DK, Purdham JT, Roels HA. Translating evidence about occupational conditions into strategies for prevention. Occup Environ Med 2002;59:205–213.[Free Full Text]
  34. Mumby S, Upton RL, Chen Y, Stanford SJ, Quinlan GJ, Nicholson AG, Gutteridge JM, Lamb NJ, Evans TW. Lung heme oxygenase-1 is elevated in acute respiratory distress syndrome. Crit Care Med 2004; 32:1130–1135.[CrossRef][Medline]
  35. Zhou H, Lu F, Latham C, Zander DS, Visner GA. Heme oxygenase-1 expression in human lungs with cystic fibrosis and cytoprotective effects against Pseudomonas aeruginosa in vitro. Am J Respir Crit Care Med 2004;170:633–640.[Abstract/Free Full Text]
  36. Kirino Y, Takeno M, Iwasaki M, Ueda A, Ohno S, Shirai A, Kanamori H, Tanaka K, Ishigatsubo Y. Increased serum HO-1 in hemophagocytic syndrome and adult-onset Still's disease: use in the differential diagnosis of hyperferritinemia. Arthritis Res Ther 2005;7:R616–R624.[CrossRef][Medline]
  37. Hnizdo E, Sluis-Cremer GK, Baskind E, Murray J. Emphysema and airway obstruction in non-smoking South African gold miners with long exposure to silica dust. Occup Environ Med 1994;51:557–563.[Abstract/Free Full Text]
  38. Foronjy RF, Mirochnitchenko O, Propokenko O, Lemaitre V, Jia Y, Inouye M, Okada Y, D'Armiento J. Supreoxide dismutase expression attenuates cigarette smoke- or elastase-generated emphysema in mice. Am J Respir Crit Care Med 2006;173:623–631.[Abstract/Free Full Text]
  39. Yasuda H, Yamaya M, Nakayama K, Ebihara S, Sasaki T, Okinaga S, Inoue D, Asada M, Nemoto M, Sasaki H. Increased arterial carboxyhemoglobin concentrations in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;171:1246–1251.[Abstract/Free Full Text]
  40. Morimoto K, Ohta K, Yachie A, Yang Y, Shimizu M, Goto C, Toma T, Kasahara Y, Yokoyama H, Miyata Y, et al. Cytoprotective role of heme oxygenase (HO)-1 in human kidney with various renal diseases. Kidney Int 2001;60:1858–1866.[CrossRef][Medline]
  41. Nath KA, Grande JP, Haggard JJ, Croatt AJ, Katusic ZS, Solovey A, Hebbel RP. Oxidative stress and induction of heme oxygenase-1 in the kidney in sickle cell disease. Am J Pathol 2001;158:893–903.[Abstract/Free Full Text]
  42. Ameriso SF, Villamil AR, Zedda C, Parodi JC, Garrido S, Sarchi MI, Schultz M, Boczkowski J, Sevlever GE. Heme oxygenase-1 is expressed in carotid atherosclerotic plaques infected by Helicobacter pylori and is more prevalent in asymptomatic subjects. Stroke 2005;36:1896–1903.[Abstract/Free Full Text]
  43. Morse D, Choi AM. Heme oxygenase-1: from bench to bedside. Am J Respir Crit Care Med 2005;172:660–670.[Abstract/Free Full Text]
  44. Auten RL, Whorton MH, Nicholas Mason S. Blocking neutrophil influx reduces DNA damage in hyperoxia-exposed newborn rat lung. Am J Respir Cell Mol Biol 2002;26:391–397.[Abstract/Free Full Text]
  45. Kinnula VL, Fattman CL, Tan RJ, Oury TD. Oxidative stress in pulmonary fibrosis: a possible role for redox modulatory therapy. Am J Respir Crit Care Med 2005;172:417–422.[Abstract/Free Full Text]
  46. Kapitulnik J. Bilirubin: an endogenous product of heme degradation with both cytotoxic and cytoprotective properties. Mol Pharmacol 2004;66:773–779.[Free Full Text]
  47. Taille C, Almolki A, Benhamed M, Zedda C, Megret J, Berger P, Leseche G, Fadel E, Yamaguchi T, Marthan R, et al. Heme oxygenase inhibits human airway smooth muscle proliferation via a bilirubin-dependent modulation of ERK1/2 phosphorylation. J Biol Chem 2003;278:27160–27168.




This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Online Supplement
Right arrow All Versions of this Article:
200508-1237OCv1
174/8/906    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sato, T.
Right arrow Articles by Ishigatsubo, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sato, T.
Right arrow Articles by Ishigatsubo, Y.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2006 American Thoracic Society